Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease
Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y, JELIS Investigators
Circulation journal : official journal of the Japanese Circulation Society · 118 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2009-01-01 · Circ J · vol. 73 · número 7 · págs. 1283–1290
- Editorial
- Japanese Circulation Society
- Citado
- 157 citas · más que el 98% de estudios similares · 9.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 35 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Fatty Acid Research and Health · Lipoproteins and Cardiovascular Health · Paraoxonase enzyme and polymorphisms
- Palabras clave
- eicosapentaenoic acid, omega-3 fatty acids, coronary artery disease, secondary prevention, statin therapy, major coronary events, myocardial infarction, hypercholesterolemia, number needed to treat
- MeSH
- humans, cardiovascular diseases, hypercholesterolemia, eicosapentaenoic acid, triglycerides, hydroxymethylglutaryl-coa reductase inhibitors, drug therapy, combination, incidence, follow-up studies, aged, middle aged, japan, female, male, cholesterol, ldl, coronary artery disease, kaplan-meier estimate
17 autores
- Masunori Matsuzaki🇯🇵Yamaguchi University
- Mitsuhiro Yokoyama🇯🇵Kobe University
- Yasushi Saitō🇯🇵Chiba University
- Hideki Origasa🇯🇵University of Toyama
- Yuichi Ishikawa🇯🇵Kobe University
- Shinichi Oikawa🇯🇵Nippon Medical School
- Junichi Sasaki🇯🇵International University of Health and Welfare
- Hitoshi Hishida🇯🇵Fujita Health University
- Hiroshige Itakura🇯🇵Ibaraki Christian University
- Toru Kita🇯🇵Kyoto University
- Akira Kitabatake
- Noriaki Nakaya
- Toshiie Sakata🇯🇵Nakamura Gakuen University
- Kazuyuki Shimada🇯🇵Jichi Medical University
- Kunio Shirato
- Yūji Matsuzawa🇯🇵Sumitomo Hospital
- The JELIS Investigators
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Results from JELIS (Japan EPA Lipid Intervention Study) demonstrated the efficacy of pure eicosapentaenoic acid (EPA) in preventing coronary artery disease (CAD) in hypercholesterolemic patients under statin treatment. The present study examined in detail whether EPA is effective for the secondary prevention of CAD.
Methods and results
Patients with established CAD and a total cholesterol level > or =250 mg/dl were observed with a mean follow-up of 4.6 years. They were randomly assigned to receive either 1,800 mg of EPA + statin (EPA group) or statin alone (control group). The incidence of major coronary events (MCE) were compared in the 2 groups. The incidence of MCE was significantly lower in the EPA group (8.7% vs 10.7%, adjusted hazard ratio =0.77, 95% confidence interval (CI) 0.63-0.96, P=0.017, number needed to treat (NNT) =49). Among 1,050 patients with prior myocardial infarction (MI), the incidence of MCE in the EPA group (15.0%) was significantly lower than that in the control group (20.1%, adjusted hazard ratio =0.73, 95%CI 0.54-0.98, P=0.033, NNT =19).
Conclusions
EPA is effective for secondary prevention of CAD, especially in individuals with prior MI, and should be added to conventional treatment.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.